Published in Nature on January 09, 1992
On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A (1996) 3.29
The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. Biochem J (2007) 2.27
Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J (1994) 2.00
Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. J Clin Invest (1994) 1.84
Impairment of macrophage functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial pigment. J Exp Med (1992) 1.78
Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem J (2002) 1.72
Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci (2011) 1.65
4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Antimicrob Agents Chemother (1996) 1.65
Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem J (1999) 1.62
HDP-a novel heme detoxification protein from the malaria parasite. PLoS Pathog (2008) 1.55
Plasmodium vivax trophozoites insensitive to chloroquine. Malar J (2008) 1.54
Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother (1993) 1.50
Speciation and structure of ferriprotoporphyrin IX in aqueous solution: spectroscopic and diffusion measurements demonstrate dimerization, but not mu-oxo dimer formation. J Biol Inorg Chem (2006) 1.45
Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun (2000) 1.37
In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother (1999) 1.35
PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol Microbiol (2006) 1.33
Combined confocal Raman and quantitative phase microscopy system for biomedical diagnosis. Biomed Opt Express (2011) 1.31
Differential stimulation of the Na+/H+ exchanger determines chloroquine uptake in Plasmodium falciparum. J Cell Biol (1998) 1.31
Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro. Antimicrob Agents Chemother (1998) 1.30
Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Antimicrob Agents Chemother (1998) 1.26
A P-glycoprotein protects Caenorhabditis elegans against natural toxins. EMBO J (1995) 1.23
Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum. Antimicrob Agents Chemother (2004) 1.21
Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect Immun (1995) 1.17
Crystallization of synthetic haemozoin (beta-haematin) nucleated at the surface of lipid particles. Dalton Trans (2009) 1.17
Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol Res (2006) 1.17
Impact of malaria on genetic polymorphism and genetic diseases in Africans and African Americans. Proc Natl Acad Sci U S A (1994) 1.16
Evaluation of pH during cytostomal endocytosis and vacuolar catabolism of haemoglobin in Plasmodium falciparum. Biochem J (2007) 1.15
Insights into the role of heme in the mechanism of action of antimalarials. ACS Chem Biol (2012) 1.14
8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents Chemother (1999) 1.12
Heme and blood-feeding parasites: friends or foes? Parasit Vectors (2010) 1.07
Hematin polymerization assay as a high-throughput screen for identification of new antimalarial pharmacophores. Antimicrob Agents Chemother (2000) 1.07
Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols. PLoS Negl Trop Dis (2009) 1.06
Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother (2009) 1.04
In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother (2002) 1.04
Malaria drug resistance: new observations and developments. Essays Biochem (2011) 1.03
Mechanism of malarial haem detoxification inhibition by chloroquine. Biochem J (2001) 1.02
A new model for hemoglobin ingestion and transport by the human malaria parasite Plasmodium falciparum. J Cell Sci (2008) 1.01
The heme biosynthesis pathway is essential for Plasmodium falciparum development in mosquito stage but not in blood stages. J Biol Chem (2014) 1.01
Zinc protoporphyrin IX binds heme crystals to inhibit the process of crystallization in Plasmodium falciparum. Mol Med (2003) 1.00
Retracted The pfmdr1 gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells. Proc Natl Acad Sci U S A (1996) 1.00
Hemozoin: oil versus water. Parasitol Int (2007) 1.00
Lipophilic mediated assays for beta-hematin inhibitors. Comb Chem High Throughput Screen (2010) 0.99
Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest (1998) 0.98
Glutathione transport: a new role for PfCRT in chloroquine resistance. Antioxid Redox Signal (2012) 0.97
Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp. Antimicrob Agents Chemother (2006) 0.96
Malarial hemozoin: from target to tool. Biochim Biophys Acta (2014) 0.96
Simple colorimetric inhibition assay of heme crystallization for high-throughput screening of antimalarial compounds. Antimicrob Agents Chemother (2006) 0.94
The chemical mechanism of beta-haematin formation studied by Mössbauer spectroscopy. Biochem J (1996) 0.93
Alpha-glucosidase promotes hemozoin formation in a blood-sucking bug: an evolutionary history. PLoS One (2009) 0.90
Antimalarial activity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yl)cyclohexane-1,2-diamine: comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737. Antimicrob Agents Chemother (1997) 0.90
The hydroxyl functionality and a rigid proximal N are required for forming a novel non-covalent quinine-heme complex. J Inorg Biochem (2010) 0.89
Involvement of heme in the antimalarial action of chloroquine. Trans Am Clin Climatol Assoc (1998) 0.89
Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum. Bioorg Med Chem (2012) 0.88
Phenotypic reversal of the btn1 defects in yeast by chloroquine: a yeast model for Batten disease. Proc Natl Acad Sci U S A (1999) 0.87
On the mechanisms involved in biological heme crystallization. J Bioenerg Biomembr (2011) 0.87
Malaria. How chloroquine works. Nature (1992) 0.86
Expression of the plasmodial pfmdr1 gene in mammalian cells is associated with increased susceptibility to chloroquine. Mol Cell Biol (1994) 0.85
Synchrony in malaria infections: how intensifying within-host competition can be adaptive. Am Nat (2013) 0.85
The single crystal X-ray structure of β-hematin DMSO solvate grown in the presence of chloroquine, a β-hematin growth-rate inhibitor. J Am Chem Soc (2013) 0.83
Chemotherapy of drug-resistant malaria. Can J Infect Dis (1996) 0.83
Regulation of heme polymerizing activity and the antimalarial action of chloroquine. Antimicrob Agents Chemother (1997) 0.83
Synthetic Hemozoin (β-Hematin) Crystals Nucleate at the Surface of Neutral Lipid Droplets that Control Their Sizes. Cryst Growth Des (2013) 0.82
Solution behavior of hematin under acidic conditions and implications for its interactions with chloroquine. J Biol Inorg Chem (2010) 0.81
Ligands of the peripheral benzodiazepine receptor are potent inhibitors of Plasmodium falciparum and Toxoplasma gondii in vitro. Antimicrob Agents Chemother (2002) 0.81
Enhancement of drug susceptibility in Plasmodium falciparum in vitro and Plasmodium berghei in vivo by mixed-function oxidase inhibitors. Antimicrob Agents Chemother (1993) 0.80
In vitro increase in chloroquine accumulation induced by dihydroethano- and ethenoanthracene derivatives in Plasmodium falciparum-parasitized erythrocytes. Antimicrob Agents Chemother (2002) 0.80
Beneficial effect of aurothiomalate on murine malaria. Malar J (2010) 0.80
Plasmodium drug targets outside the genetic control of the parasite. Curr Pharm Des (2013) 0.79
The mechanism of antimalarial action of [Au(CQ)(PPh(3))]PF(6): structural effects and increased drug lipophilicity enhance heme aggregation inhibition at lipid/water interfaces. J Inorg Biochem (2010) 0.79
Chloroquine neither eliminates liver stage parasites nor delays their development in a murine Chemoprophylaxis Vaccination model. Front Microbiol (2015) 0.78
Quinine localizes to a non-acidic compartment within the food vacuole of the malaria parasite Plasmodium falciparum. Malar J (2012) 0.78
Plasmodium falciparum enolase complements yeast enolase functions and associates with the parasite food vacuole. Mol Biochem Parasitol (2011) 0.78
Predicting functional and regulatory divergence of a drug resistance transporter gene in the human malaria parasite. BMC Genomics (2015) 0.77
An integrative analysis of small molecule transcriptional responses in the human malaria parasite Plasmodium falciparum. BMC Genomics (2015) 0.77
Plasmodium falciparum: Assessment of Selectivity of Action of Chloroquine, Alchornea cordifolia, Ficus polita, and Other Drugs by a Tetrazolium-Based Colorimetric Assay. Malar Res Treat (2011) 0.77
Hemozoin and antimalarial drug discovery. Future Med Chem (2013) 0.77
Biliverdin targets enolase and eukaryotic initiation factor 2 (eIF2α) to reduce the growth of intraerythrocytic development of the malaria parasite Plasmodium falciparum. Sci Rep (2016) 0.77
Characterization of the chloroquine resistance transporter homologue in Toxoplasma gondii. Eukaryot Cell (2014) 0.76
Hemozoin from Schistosoma japonicum does not affect murine myeloid dendritic cell function. Parasitol Res (2010) 0.76
Superparamagnetic Properties of Hemozoin. Sci Rep (2016) 0.75
Using a genome-scale metabolic network model to elucidate the mechanism of chloroquine action in Plasmodium falciparum. Int J Parasitol Drugs Drug Resist (2017) 0.75
Inhibition of autophagy with bafilomycin and chloroquine decreases mitochondrial quality and bioenergetic function in primary neurons. Redox Biol (2016) 0.75
Digestion and indigestion in malaria parasites. J Clin Invest (1994) 0.75
Nanocrystallography measurements of early stage synthetic malaria pigment. J Appl Crystallogr (2017) 0.75
Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis (2014) 0.75
Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria. Mamm Genome (2011) 0.75
Quinolines block every step of malaria heme crystal growth. Proc Natl Acad Sci U S A (2017) 0.75
Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A (1986) 15.20
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (1986) 11.09
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol (1989) 9.63
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (1986) 9.19
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med (1985) 8.18
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 7.22
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med (1988) 7.22
Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med (1994) 7.19
Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med (1976) 7.02
TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet (1990) 6.32
Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem (1988) 5.75
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature (1993) 5.60
Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol (1985) 5.38
MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 5.21
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A (2000) 5.20
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A (1984) 4.04
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med (1994) 3.95
Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A (1989) 3.88
Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med (1991) 3.81
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A (2001) 3.80
Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med (1981) 3.70
Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A (1982) 3.69
Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol (1993) 3.68
Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J (1989) 3.67
Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 3.58
Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol (1992) 3.57
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science (1986) 3.36
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. Proc Natl Acad Sci U S A (1971) 3.27
Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science (1981) 3.25
Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med (1984) 3.14
Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties. J Exp Med (1988) 3.06
Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem (1992) 3.06
Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: role of defective triglyceride removal. Mol Biochem Parasitol (1980) 3.05
Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci U S A (1990) 3.01
Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest (1991) 3.00
Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science (1985) 2.94
The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med (1990) 2.89
Cachectin/tumour necrosis factor. Lancet (1989) 2.77
An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature (1996) 2.71
Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol (1988) 2.66
Macrophage inflammatory protein 1 modulates macrophage function. J Immunol (1992) 2.66
Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med (2008) 2.55
Protein glycation, diabetes, and aging. Recent Prog Horm Res (2001) 2.51
Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues. J Exp Med (1990) 2.44
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
An iron-carboxylate bond links the heme units of malaria pigment. Proc Natl Acad Sci U S A (1991) 2.36
Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med (1991) 2.32
Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J Exp Med (1986) 2.28
Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci U S A (1984) 2.26
Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett (1985) 2.23
Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med (1989) 2.21
Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol (1985) 2.21
Structure of carbohydrate of hemoglobin AIc. J Biol Chem (1977) 2.21
Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A (1992) 2.20
Lipopolysaccharide-treated RAW 264.7 cells produce a mediator that inhibits lipoprotein lipase in 3T3-L1 cells. J Immunol (1985) 2.15
Diabetic cataract formation: potential role of glycosylation of lens crystallins. Proc Natl Acad Sci U S A (1978) 2.14
High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci U S A (1985) 2.11
Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A (1997) 2.10
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A (1992) 2.09
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest (1990) 2.08
Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol (1992) 2.04
Lipoprotein lipase suppression in 3T3-L1 cells by a haematoprotozoan-induced mediator from peritoneal exudate cells. Parasite Immunol (1984) 2.03
Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A (1996) 2.02
Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A (1993) 2.00
Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol (1993) 1.99
Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol (1989) 1.99
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98
In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol Biochem Parasitol (1987) 1.97
Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis (1988) 1.94
Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A (1998) 1.92
Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int (2006) 1.91
Effects of iron chelators and iron overload on Salmonella infection. Nature (1977) 1.89
Synthesis of hemoglobin AIc in normal and diabetic mice: potential model of basement membrane thickening. Proc Natl Acad Sci U S A (1975) 1.84
Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J (1989) 1.82
Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med (1988) 1.82
The common mediator of shock, cachexia, and tumor necrosis. Adv Immunol (1988) 1.80
A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med (1990) 1.80
Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J Exp Med (1991) 1.80
Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med (1991) 1.78
Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A (1994) 1.78
Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med (1997) 1.70
Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. J Exp Med (1988) 1.68
Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A (1983) 1.68
An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A (2000) 1.68
The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem (1981) 1.66
The interaction of actinomycin with DNA: requirement for the 2-amino group of purines. Proc Natl Acad Sci U S A (1967) 1.65
Infection and labor. IV. Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. Am J Obstet Gynecol (1989) 1.62
Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. J Inflamm (1995) 1.62
Purification and characterization of trypanothione reductase from Crithidia fasciculata, a newly discovered member of the family of disulfide-containing flavoprotein reductases. Biochemistry (1986) 1.62